Abstract
While conventional cytodiagnosis can, in most instances, recognize cancer cells in metastatic effusions from solid tumors, the cellular type or the organ of origin of the primary neoplasia can rarely be determined only on the basis of their morphology. In the present study we have evaluated whether immunocytochemical techniques can be used to overcome this limitation by employing a panel of monoclonal antibodies (MoAbs) to tumor associated antigens (TAA) which lack detectable reactivity with mesothelial cells. To this end we have analyzed, by indirect immunofluorescence, cytospins of 60 malignant effusions of unknown origin. The results of this study have shown that the definition of the origin of the primary tumor, which was subsequently confirmed histologically and/or clinically, could be reached in 87% of the cases. These findings demonstrate that selected combinations of MoAbs, when used in immunocytochemical tests, can provide a powerful diagnostic tool in defining the site of cryptic primary neoplasias causing metastatic effusions.
| Original language | English |
|---|---|
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 24 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. / Mottolese, M.; Venturo, I.; Perrone Donnorso, R.; Gallo Curcio, C.; Rinaldi, M.; Natali, P. G.
In: European Journal of Cancer and Clinical Oncology, Vol. 24, No. 8, 1988.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin
AU - Mottolese, M.
AU - Venturo, I.
AU - Perrone Donnorso, R.
AU - Gallo Curcio, C.
AU - Rinaldi, M.
AU - Natali, P. G.
PY - 1988
Y1 - 1988
N2 - While conventional cytodiagnosis can, in most instances, recognize cancer cells in metastatic effusions from solid tumors, the cellular type or the organ of origin of the primary neoplasia can rarely be determined only on the basis of their morphology. In the present study we have evaluated whether immunocytochemical techniques can be used to overcome this limitation by employing a panel of monoclonal antibodies (MoAbs) to tumor associated antigens (TAA) which lack detectable reactivity with mesothelial cells. To this end we have analyzed, by indirect immunofluorescence, cytospins of 60 malignant effusions of unknown origin. The results of this study have shown that the definition of the origin of the primary tumor, which was subsequently confirmed histologically and/or clinically, could be reached in 87% of the cases. These findings demonstrate that selected combinations of MoAbs, when used in immunocytochemical tests, can provide a powerful diagnostic tool in defining the site of cryptic primary neoplasias causing metastatic effusions.
AB - While conventional cytodiagnosis can, in most instances, recognize cancer cells in metastatic effusions from solid tumors, the cellular type or the organ of origin of the primary neoplasia can rarely be determined only on the basis of their morphology. In the present study we have evaluated whether immunocytochemical techniques can be used to overcome this limitation by employing a panel of monoclonal antibodies (MoAbs) to tumor associated antigens (TAA) which lack detectable reactivity with mesothelial cells. To this end we have analyzed, by indirect immunofluorescence, cytospins of 60 malignant effusions of unknown origin. The results of this study have shown that the definition of the origin of the primary tumor, which was subsequently confirmed histologically and/or clinically, could be reached in 87% of the cases. These findings demonstrate that selected combinations of MoAbs, when used in immunocytochemical tests, can provide a powerful diagnostic tool in defining the site of cryptic primary neoplasias causing metastatic effusions.
UR - http://www.scopus.com/inward/record.url?scp=0023755334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023755334&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(88)90215-5
DO - 10.1016/0277-5379(88)90215-5
M3 - Article
VL - 24
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 8
ER -